Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RZ-629 in Healthy Subjects and T2D
Recruiting now · Phase 1 · Has a placebo group
Conditions studied: Diabetes
In brief
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) biomarkers in single ascending doses (SAD), food effect, and multiple doses studies of RZ-629 in healthy participants and T2D.
Key facts
- Study ID
- NCT06829563
- Run by
- Rezubio Pharmaceuticals Co., Ltd.
- People needed
- 134
- Starts
- 2025-01-30
- Expected to finish
- 2026-02-20
- Last updated by the study team
- 2025-08-21
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.
Where it is running
- CMAX — Adelaide, Australia (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.